A multicentre randomized double-blind placebo-controlled study of lacosamide, pregabalin, and tapentadol on spinal pain biomarkers

Key Points

• RIII threshold serves as an effective spinal biomarker for assessing antihyperalgesic drug effects.
• The study highlights the importance of optimal timing and analysis strategies for analgesic research.
• Randomized double-blind placebo-controlled study evaluated the impact of multiple drugs on spinal pain biomarkers.
• Findings may inform future decisions regarding drug selection and biomarker usage in pain management.